The 2024 International Myeloma Society Annual Meeting was a groundbreaking event that showcased the latest advancements in multiple myeloma research and treatment.
The 2024 International Myeloma Society Annual Meeting was a groundbreaking event that showcased the latest advancements in multiple myeloma research and treatment. Held in Rio de Janeiro, Brazil, the meeting brought together leading experts from around the world to discuss the latest findings in clinical trials, novel therapeutic approaches, and emerging technologies. Attendees had the opportunity to learn about new treatment options, hear about promising clinical trial results, and network with other professionals in the field. The meeting highlighted the significant progress that has been made in recent years in improving outcomes for patients with multiple myeloma.
Here are our highlights from this year’s meeting.
Updated results from the phase 1b TRIMM-2 study (NCT04108195) indicate that the combination of talquetamab-tgvs (Talvey), daratumumab with hyaluronidase-fihj (Darzalex Faspro), and pomalidomide (Pomalyst) produced deep and durable responses in patients with relapsed/refractory multiple myeloma, achieving an overall response rate (ORR) of 82%.
In the phase 3 CEPHEUS trial (NCT03652064), the addition of subcutaneous daratumumab to the VRd regimen (bortezomib [Velcade], lenalidomide [Revlimid], and dexamethasone) improved minimal residual disease (MRD) negativity rates compared to VRd alone in newly diagnosed patients with multiplemyeloma who were either ineligible for or deferred transplant.
Treatment with the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) reduced the risk of death by 45% vs standard of care in patients with lenalidomide-refractory multiple myeloma and at least 1 prior line of therapy, according to updated results from the phase 3 CARTITUDE-4 trial.
Findings from a phase 1 (NCT04155749) trial evaluating the BCMA-directed CAR T-cell therapy, anitocabtagene autoleucel (anito-cel; CART-ddBCMA), demonstrated impressive and durable efficacy rates in patients with relapsed/refractory multiple myeloma.
Talquetamab plus teclistamab-cqyv (Tecvayli) delivered a high rate of durable responses in patients with triple-class exposed relapsed/refractory multiple myeloma, according to findings from the phase 1b RedirecTT-1 study (NCT04586426).
Ashraf Z. Badros, MB, ChB, professor of medicine, director of the Multiple Myeloma Service, and vice chair of the Clinical Research Committee for the Program in Oncology at the University of Maryland School of Medicine in Baltimore, discusses the key takeaways from the phase 3 AURIGA trial (NCT03901963).
CAR T and CRS Adverse Events Considered in Relapsed Multiple Myeloma
October 24th 2024During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for a patient with relapsed/refractory multiple myeloma and relevance of the KarMMa-3 trial for their treatment.
Read More
Functional High Risk and Bridging in Multiple Myeloma Considered With CAR T Cells
October 9th 2024Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with relapsed/refractory multiple myeloma and functional high risk, bridging to cilta-cel, and time to treatment in the second article of a 2-part series.
Read More
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma
October 7th 2024A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.
Read More